| General Information | |
|---|---|
| ZINC ID | ZINC000101206643 |
| Molecular Weight (Da) | 381 |
| SMILES | CC1=CC[C@@H]2[C@@H](C1)c1c(O)cc([C@@H]3C[C@@H]4CC[C@]3(C)C4(C)C)cc1OC2(C)C |
| Molecular Formula | C26O2 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 115.385 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 1 |
| Heavy Atoms | 28 |
| LogP | 6.305 |
| Activity (Ki) in nM | 6.166 |
| Polar Surface Area (PSA) | 29.46 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | + |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | + |
| Cyp2d6 substrate | + |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | + |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.944 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 6 |
| Fraction csp3 | 0.69 |
| Ilogp | 0 |
| Xlogp3 | 8.31 |
| Wlogp | 6.93 |
| Mlogp | 5.45 |
| Silicos-it log p | 6 |
| Consensus log p | 5.34 |
| Esol log s | -7.53 |
| Esol solubility (mg/ml) | 0.0000113 |
| Esol solubility (mol/l) | 2.97E-08 |
| Esol class | Poorly sol |
| Ali log s | -8.79 |
| Ali solubility (mg/ml) | 0.00000061 |
| Ali solubility (mol/l) | 1.61E-09 |
| Ali class | Poorly sol |
| Silicos-it logsw | -6.5 |
| Silicos-it solubility (mg/ml) | 0.000121 |
| Silicos-it solubility (mol/l) | 0.00000031 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -2.72 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 1 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 5.81 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -3.7 |
| Logd | 5.359 |
| Logp | 8.387 |
| F (20%) | 0.998 |
| F (30%) | 0.991 |
| Mdck | 1.38E-05 |
| Ppb | 0.9904 |
| Vdss | 6.434 |
| Fu | 0.0357 |
| Cyp1a2-inh | 0.104 |
| Cyp1a2-sub | 0.638 |
| Cyp2c19-inh | 0.486 |
| Cyp2c19-sub | 0.907 |
| Cl | 9.216 |
| T12 | 0.04 |
| H-ht | 0.89 |
| Dili | 0.187 |
| Roa | 0.743 |
| Fdamdd | 0.972 |
| Skinsen | 0.327 |
| Ec | 0.004 |
| Ei | 0.06 |
| Respiratory | 0.877 |
| Bcf | 3.062 |
| Igc50 | 5.109 |
| Lc50 | 6.689 |
| Lc50dm | 6.621 |
| Nr-ar | 0.365 |
| Nr-ar-lbd | 0.189 |
| Nr-ahr | 0.029 |
| Nr-aromatase | 0.698 |
| Nr-er | 0.398 |
| Nr-er-lbd | 0.816 |
| Nr-ppar-gamma | 0.764 |
| Sr-are | 0.6 |
| Sr-atad5 | 0.068 |
| Sr-hse | 0.168 |
| Sr-mmp | 0.966 |
| Sr-p53 | 0.718 |
| Vol | 422.504 |
| Dense | 0.9 |
| Flex | 0.042 |
| Nstereo | 5 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 1 |
| Qed | 0.535 |
| Synth | 5.024 |
| Fsp3 | 0.692 |
| Mce-18 | 117 |
| Natural product-likeness | 2.497 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Rejected |
| Goldentriangle | Rejected |